Home Companies Catalysts Deep Dives

Diffuse large B-cell lymphoma

DLBCL · Oncology · 6 drugs · 6 indications

Aggressive B-cell non-Hodgkin lymphoma.
Competitive Landscape (6 drugs)
DrugCompanyMechanismModalityRouteStage
OdronextamabREGNCD20xCD3 bispecificBispecific antibodyIVPHASE3
PolivyROG.SWCD79b-targeted (MMAE payload)ADCIVAPPROVED
ColumviROG.SWCD20xCD3 T-cell engagerBispecificIVAPPROVED
YescartaGILDCD19 CAR-TCell therapyIVAPPROVED
EpkinlyABBV, GMABCD20xCD3 bispecificBispecificSCAPPROVED
ZynlontaSOBIAnti-CD19 antibody-drug conjugateAntibody-drug conjugateIVAPPROVED
Indications (6)
Relapsed/refractory DLBCL (3L+)
Odronextamab PHASE3Zynlonta APPROVED
R/R DLBCL
Polivy APPROVEDColumvi APPROVEDYescarta APPROVEDEpkinly APPROVED
1L DLBCL
Epkinly PHASE3
2L DLBCL transplant ineligible
Epkinly PHASE3
Relapsed/refractory large B-cell lymphoma, 3L+
Relapsed/refractory DLBCL (2L)
Zynlonta PHASE3
Upcoming Catalysts
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)CLINICAL
ABBVH1 2026
Zynlonta - R/R DLBCL 2L - Ph3 - Data (LOTIS-5)CLINICAL
SOBIH1/H2 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)CLINICAL
ABBVH2 2026
Yescarta - 1L High-Risk LBCL - RMAT DataCLINICAL
GILD2026
Odronextamab - R/R FL - Ph3 ToplineCLINICAL
REGN2026-2027
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)CLINICAL
GMABH2 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)CLINICAL
GMABH2 2026
Data from Supabase · Updated 2026-03-24